Pacira BioSciences, Inc. (PCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.46B
Last updated: Nov 17, 2026 at 3:04 AM ET
Pacira BioSciences, Inc. (PCRX) Earnings: Report Dates and Results
Pacira BioSciences (PCRX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Pacira BioSciences reported EPS of $0.46, below the $0.47 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PCRX has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 162.5% above the $0.32 reported for the quarter ended Dec 31, 2025.
PCRX Earnings Call
The latest PCRX earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 40 quarters below that had an estimate, PCRX beat 26, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $176.65M, down 1.6% from $179.52M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.46 | $0.47 | N/A | -2.13% | Miss | -34.3% | 9 | 1 up, 0 down | Nov 5, 2026 | $176.65M |
| Jun 30, 2026 | $0.44 | $0.27 | N/A | +62.96% | Beat | -40.5% | 6 | 1 up, 6 down | Aug 4, 2026 | $192.40M |
| Mar 31, 2026 | $0.60 | $0.56 | $0.46 - $0.65 | +7.14% | Beat | -3.2% | 7 | 0 up, 1 down | Apr 30, 2026 | $177.38M |
| Dec 31, 2025 | $0.32 | $0.60 | N/A | -46.67% | Miss | -64.8% | 7 | 1 up, 1 down | Feb 26, 2026 | $196.87M |
| Sep 30, 2025 | $0.70 | $0.65 | $0.62 - $0.71 | +7.69% | Beat | -11.4% | 6 | 0 up, 1 down | Nov 6, 2025 | $179.52M |
| Jun 30, 2025 | $0.74 | $0.71 | $0.64 - $0.81 | +4.23% | Beat | -16.9% | 6 | 1 up, 0 down | Aug 5, 2025 | $181.10M |
| Mar 31, 2025 | $0.62 | $0.60 | $0.49 - $0.77 | +3.33% | Beat | 0.0% | 7 | 2 up, 0 down | May 8, 2025 | $168.92M |
| Dec 31, 2024 | $0.91 | $0.83 | $0.62 - $0.95 | +9.60% | Beat | +2.2% | 7 | 3 up, 0 down | Feb 27, 2025 | $187.25M |
| Sep 30, 2024 | $0.79 | $0.70 | $0.58 - $0.93 | +12.86% | Beat | +9.7% | 9 | 0 up, 0 down | Nov 6, 2024 | $168.57M |
| Jun 30, 2024 | $0.89 | $0.70 | $0.53 - $0.83 | +27.14% | Beat | +14.1% | 9 | 2 up, 0 down | Jul 30, 2024 | $178.02M |
| Mar 31, 2024 | $0.62 | $0.62 | $0.50 - $0.80 | 0.00% | In line | +17.0% | 9 | 0 up, 1 down | May 7, 2024 | $167.12M |
| Dec 31, 2023 | $0.89 | $0.87 | $0.75 - $0.98 | +2.30% | Beat | +11.2% | 8 | 2 up, 0 down | Feb 29, 2024 | $181.24M |
| Sep 30, 2023 | $0.72 | $0.78 | $0.68 - $0.87 | -7.69% | Miss | +12.5% | 8 | 0 up, 1 down | Nov 2, 2023 | $163.93M |
| Jun 30, 2023 | $0.78 | $0.76 | $0.48 - $0.87 | +2.63% | Beat | +52.9% | 8 | 0 up, 1 down | Aug 2, 2023 | $169.47M |
| Mar 31, 2023 | $0.53 | $0.62 | $0.56 - $0.69 | -14.52% | Miss | -17.2% | 8 | 2 up, 0 down | May 3, 2023 | $160.34M |
| Dec 31, 2022 | $0.80 | $0.83 | $0.70 - $0.98 | -3.61% | Miss | -17.5% | 9 | 0 up, 0 down | Feb 28, 2023 | $838.78M |
| Sep 30, 2022 | $0.64 | $0.76 | $0.50 - $0.88 | -15.79% | Miss | -11.1% | 11 | 0 up, 2 down | Nov 3, 2022 | $167.47M |
| Jun 30, 2022 | $0.51 | $0.85 | $0.74 - $1.16 | -40.00% | Miss | -33.8% | 10 | 2 up, 0 down | Aug 3, 2022 | $169.41M |
| Mar 31, 2022 | $0.64 | $0.83 | $0.56 - $1.09 | -22.89% | Miss | +20.8% | 11 | 2 up, 0 down | May 4, 2022 | $157.99M |
| Dec 31, 2021 | $0.97 | $0.90 | $0.67 - $1.70 | +7.78% | Beat | +11.5% | 12 | 1 up, 0 down | Feb 24, 2022 | $159.19M |
| Sep 30, 2021 | $0.72 | $0.65 | N/A | +10.77% | Beat | +5.9% | 12 | 2 up, 0 down | Nov 3, 2021 | $127.72M |
| Jun 30, 2021 | $0.77 | $0.74 | $0.63 - $0.91 | +4.05% | Beat | +541.7% | 12 | N/A | Aug 3, 2021 | $135.59M |
| Mar 31, 2021 | $0.53 | $0.63 | $0.41 - $0.91 | -15.87% | Miss | 0.0% | 13 | N/A | May 4, 2021 | $119.03M |
| Dec 31, 2020 | $0.87 | $0.81 | $0.62 - $0.97 | +7.41% | Beat | +55.4% | 15 | N/A | Feb 25, 2021 | $130.97M |
| Sep 30, 2020 | $0.68 | $0.65 | $0.42 - $0.74 | +4.62% | Beat | +41.7% | 14 | N/A | Oct 29, 2020 | $117.48M |
| Jun 30, 2020 | $0.12 | $0.09 | -$0.21 - $0.35 | +33.33% | Beat | -70.7% | 14 | N/A | Aug 6, 2020 | $75.50M |
| Mar 31, 2020 | $0.53 | $0.30 | $0.14 - $0.49 | +76.67% | Beat | +140.9% | 16 | N/A | May 7, 2020 | $105.68M |
| Dec 31, 2019 | $0.56 | $0.44 | $0.28 - $0.55 | +27.27% | Beat | +19.1% | 14 | N/A | Feb 20, 2020 | $122.42M |
| Sep 30, 2019 | $0.48 | $0.33 | $0.24 - $0.42 | +45.45% | Beat | +54.8% | 15 | N/A | Nov 7, 2019 | $104.69M |
| Jun 30, 2019 | $0.41 | $0.34 | $0.19 - $0.42 | +20.59% | Beat | +70.8% | 15 | N/A | Aug 8, 2019 | $102.60M |
| Mar 31, 2019 | $0.22 | $0.26 | $0.13 - $0.43 | -15.38% | Miss | +1000.0% | 14 | N/A | May 2, 2019 | $91.31M |
| Dec 31, 2018 | $0.47 | $0.28 | $0.04 - $0.45 | +67.86% | Beat | +23.7% | 15 | N/A | Feb 28, 2019 | $95.11M |
| Sep 30, 2018 | $0.31 | $0.08 | $0.01 - $0.13 | +287.50% | Beat | +181.8% | 15 | N/A | Nov 1, 2018 | $83.45M |
| Jun 30, 2018 | $0.24 | $0.07 | -$0.03 - $0.20 | +242.86% | Beat | N/A | 18 | N/A | Aug 2, 2018 | $84.11M |
| Mar 31, 2018 | $0.02 | $0.03 | -$0.13 - $0.17 | -33.33% | Miss | N/A | 18 | N/A | May 3, 2018 | $74.61M |
| Dec 31, 2017 | $0.38 | $0.10 | -$0.08 - $0.25 | +280.00% | Beat | +322.2% | 18 | N/A | Feb 28, 2018 | $79.08M |
| Sep 30, 2017 | $0.11 | -$0.07 | -$0.29 - $0.09 | +257.14% | Beat | -45.0% | 15 | N/A | Nov 8, 2017 | $67.33M |
| Jun 30, 2017 | -$0.11 | -$0.05 | -$0.27 - $0.07 | -120.00% | Miss | -157.9% | 12 | N/A | Aug 2, 2017 | $70.93M |
| Mar 31, 2017 | -$0.19 | -$0.04 | N/A | -375.00% | Miss | -235.7% | N/A | N/A | May 4, 2017 | $69.28M |
| Dec 31, 2016 | $0.09 | $0.01 | N/A | +800.00% | Beat | -55.0% | N/A | N/A | Mar 1, 2017 | $72.90M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.38, down 25.9% from the year before. It was $0.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.38 | -25.9% |
| Dec 31, 2024 | $3.21 | +9.9% |
| Dec 31, 2023 | $2.92 | +12.7% |
| Dec 31, 2022 | $2.59 | -13.4% |
| Dec 31, 2021 | $2.99 | +35.9% |
| Dec 31, 2020 | $2.20 | +31.7% |
| Dec 31, 2019 | $1.67 | +60.6% |
| Dec 31, 2018 | $1.04 | +447.4% |
| Dec 31, 2017 | $0.19 | -69.4% |
| Dec 31, 2016 | $0.62 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,900 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 4,895 | 11 | |
| 2026Q1 | Mar 31, 2026 | 4,952 | 11 | |
| 2025Q4 | Dec 31, 2025 | 6,108 | 11 | |
| 2025Q3 | Sep 30, 2025 | 5,902 | 10 | |
| 2025Q2 | Jun 30, 2025 | 5,767 | 10 | |
| 2025Q1 | Mar 31, 2025 | 6,211 | 11 | |
| 2024Q4 | Dec 31, 2024 | 6,134 | 11 | |
| 2024Q3 | Sep 30, 2024 | 4,373 | 10 |
2026Q2 Earnings Call
Opening remarks
Susan Mesco Head of Investor Relations Thank you. Good afternoon, everyone. Welcome to today's conference call to discuss our Second Quarter of 2026 Financial Results. Joining me are Frank Lee, Chief Executive Officer, Brendan Teehan, Chief Commercial Officer, and Shawn Cross, Chief Financial Officer. Kristen Williams, Chief Administrative Officer and Secretary, Anthony Molloy, Chief Legal Officer, and Jonathan Slonin, Chief Medical Officer, are also here for today's question and answer session. Before we begin, let me remind you that this call will include forward-looking statements subject to the safe harbor provisions of federal securities laws. These statements represent our judgment as of today and may involve risks and uncertainties. This may cause our actual results, performance, or achievements to differ materially. For information concerning risk factors that could affect the company, please refer to our filings with the SEC or the Pacira website. Lastly, as a reminder, we will be discussing non-GAAP financial measures on today's call. A description of these metrics along with our reconciliation to GAAP can be found in the news release issued this afternoon. With that, I will now turn the call over to Frank Lee.
Frank Lee Chief Executive Officer Thank you, Susan, and good afternoon to everyone joining today's call. On behalf of the remarkable team here at Pacira, I'm pleased to share our continued progress in executing our 5x30 strategy and transitioning into a more innovation-driven pharmaceutical company. Our second quarter performance reflects disciplined execution of our 5x30 strategy, translating into commercial momentum, strong cash generation, pipeline advancement, and high-caliber partnerships. Furthermore, our 5x30 progress was clearly recognized with a decisive shareholder vote for both our strategy and director nominees at our annual meeting in June. Notable second quarter accomplishments include revenues of more than $109 million, even as macroeconomic pressures weighed on certain elective procedures in the hospital setting. Adjusted EBITDA of nearly $50 million. Establishing a scalable, commercially viable, U.S.-based manufacturing process for PCRX-201, a testament to our team's clinical development and manufacturing capabilities. Opening enrollment in Part B of our Phase 2 ASCENT study for PCRX-201, completing enrollment in the iovera registrational study in spasticity, and completing the iovera divestiture on July 31st, and forming a partnership in spasticity with Zimmer Biomet. I'd like to thank the Pacira and Zimmer Biomet teams for working so collaboratively and efficiently over the past 30 days to close this transaction. I look forward to continued partnership with our Zimmer Biomet colleagues going forward. I'll begin with a high-level overview of EXPAREL, and then Brendan will cover additional commercial details shortly. EXPAREL continues to penetrate and gain share across all segments, despite softness in certain deferrable soft tissue procedures, which historically wax and wane with macroeconomic conditions.
Frequently Asked Questions About PCRX
When is Pacira BioSciences's next earnings date?
Pacira BioSciences's next earnings report is expected for Feb 24, 2027.
Did PCRX beat earnings estimates last quarter?
No. Pacira BioSciences reported EPS of $0.46 for the quarter ended Sep 30, 2026, below the $0.47 estimate by 2.13%.
What EPS do analysts expect from PCRX next quarter?
The consensus EPS estimate for Pacira BioSciences for the quarter ending Dec 31, 2026 is $0.84 from 11 analysts, with estimates from $0.70 to $0.98.
How often does PCRX beat earnings estimates?
Pacira BioSciences beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +5.77%.
PCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors